Figure 3. Antivirals are a novel class of anti-fibrotic compounds in RDEB.

(A) Pie chart visual showing detachment trends across the original 1443 compounds in one RDEB fibroblast matrix assay. (B) Pie chart visual showing detachment trends in 170 compounds in a second RDEB fibroblast matrix assay. (C) Pie chart visual showing drug class hit-targets from both detachment assay screens. (D) Graph of detachment assay results of steroid hits that delayed detachment in both RDEB patient populations (n = 2, 2 biological replicates in 2–3 technical replicates). (E) Graphs of viability from steroid hits after 7 days (n = 2, 2 biological replicates in 2–3 technical replicates). (F) Graph of detachment assay results of kinase inhibitor hits that delayed detachment in both RDEB patient populations (n = 2, 2 biological replicates in 2–3 technical replicates). (G) Graphs of viability from kinase inhibitor hits after 7 days (n = 2, 2 biological replicates in 2–3 technical replicates). (H) Graph of detachment assay results (mean $\pm$ SEM) of antiviral and antimalarial hits that delayed detachment in both RDEB patient populations (n = 2, 2 biological replicates in 2–3 technical replicates). (I) Graphs of viability (mean $\pm$ SEM) from antiviral and antimalarial hits after 7 days (n = 2, 2 biological replicates in 2–3 technical replicates). (J) Graph of detachment assay results (mean $\pm$ SEM) of non-grouped “other” hits that delayed detachment in both RDEB patient populations (n = 2, 2 biological replicates in 2–3 technical replicates). (K) Graphs of viability from non-grouped “other” hits after 7 days (n = 2, 2 biological replicates in 2–3 technical replicates). Data information: In (D–G, K), data are presented as mean $\pm$ SEM, and statistical analysis was performed with ordinary one-way ANOVA corrected with Dunnett’s test. *P ≤ 0.05, ***P ≤ 0.001. Source data are available online for this figure.